Literature DB >> 25205654

miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.

Hua Sui1, Guo-Xiang Cai2, Shu-Fang Pan3, Wan-Li Deng4, Yu-Wei Wang2, Zhe-Sheng Chen5, San-Jun Cai2, Hui-Rong Zhu1, Qi Li6.   

Abstract

MicroRNA-200c (miR200c) recently emerged as an important regulator of tumorigenicity and cancer metastasis; however, its role in regulating multidrug resistance (MDR) remains unknown. In the current study, we found that the expression levels of miR200c in recurrent and metastatic colorectal cancers were significantly lower, whereas the JNK2 expression was higher compared with primary tumors. We showed that in MDR colorectal cancer cells, miR200c targeted the 3' untranslated region of the JNK2 gene. Overexpression of miR200c attenuated the levels of p-JNK, p-c-Jun, P-gp, and MMP-2/-9, the downstream factors of the JNK signaling pathway, resulting in increased sensitivity to chemotherapeutic drugs, which was accompanied by heightened apoptosis and decreased cell invasion and migration. Moreover, in an orthotopic MDR colorectal cancer mouse model, we demonstrated that overexpression of miR200c effectively inhibited the tumor growth and metastasis. At last, in the tumor samples from patients with locally advanced colorectal cancer with routine postsurgical chemotherapy, we observed an inverse correlation between the levels of mRNA expression of miR200c and JNK2, ABCB1, and MMP-9, thus predicting patient therapeutic outcomes. In summary, we found that miR200c negatively regulated the expression of JNK2 gene and increased the sensitivity of MDR colorectal cancer cells to chemotherapeutic drugs, via inhibiting the JNK2/p-JNK/p-c-Jun/ABCB1 signaling. Restoration of miR200c expression in MDR colorectal cancer may serve as a promising therapeutic approach in MDR-induced metastasis. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25205654     DOI: 10.1158/1535-7163.MCT-14-0167

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  30 in total

1.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 2.  Gastrointestinal cancer drug resistance: the role of exosomal miRNAs.

Authors:  Mahsa Salehi; Asma Vafadar; Seyyed Hossein Khatami; Mortaza Taheri-Anganeh; Omid Vakili; Amir Savardashtaki; Babak Negahdari; Parisa Naeli; Hamid Behrouj; Hassan Ghasemi; Ahmad Movahedpour
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

Review 3.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.

Authors:  Merve Mutlu; Umar Raza; Özge Saatci; Erol Eyüpoğlu; Emre Yurdusev; Özgür Şahin
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

Review 4.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

5.  Zhi Zhen Fang formula reverses Hedgehog pathway mediated multidrug resistance in colorectal cancer.

Authors:  Hua Sui; Peiwen Duan; Piaoting Guo; Lishuang Hao; Xuan Liu; Jinhua Zhang; Huirong Zhu; Miaomiao Zhao; Hao Wang; Qi Li; Songpo Wang
Journal:  Oncol Rep       Date:  2017-08-23       Impact factor: 3.906

6.  Drug resistance and combating drug resistance in cancer.

Authors:  Xuan Wang; Haiyun Zhang; Xiaozhuo Chen
Journal:  Cancer Drug Resist       Date:  2019-06-19

7.  5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway.

Authors:  Hua Sui; Hanchen Xu; Qing Ji; Xuan Liu; Lihong Zhou; Haiyan Song; Xiqiu Zhou; Yangxian Xu; Zhesheng Chen; Jianfeng Cai; Guang Ji; Qi Li
Journal:  Oncotarget       Date:  2015-09-22

8.  MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).

Authors:  Lin Zhao; Yan Wang; Longyang Jiang; Miao He; Xuefeng Bai; Lifeng Yu; Minjie Wei
Journal:  J Exp Clin Cancer Res       Date:  2016-02-03

9.  Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.

Authors:  Pengjun Zhou; Rong Zhang; Ying Wang; Dandan Xu; Li Zhang; Jinhong Qin; Guifeng Su; Yue Feng; Hongce Chen; Siyuan You; Wen Rui; Huizhong Liu; Suhong Chen; Hongyuan Chen; Yifei Wang
Journal:  Oncotarget       Date:  2017-11-27

10.  Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2.

Authors:  Linrong Pang; Jinger Lu; Jia Huang; Caihong Xu; Hui Li; Guangbo Yuan; Xiaochun Cheng; Jun Chen
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.